Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Aura, Atara, Bicycle, Biogen, Cancer Prevention, Celltrion, Clene, Galapagos, Genentech, GW, Immunic, Lilly, Lyra, Neurocrine, Novartis, Partner, Prothena, Reveragen, Santhera, Voyager.

A pivotal test of Satsuma Pharmaceuticals Inc.'s dry powder acute migraine candidate, STS-101, found neither of two doses evaluated met the co-primary endpoints, freeing people from pain or their most bothersome symptom two hours post-administration.

HONG KONG – Sanofi SA has finally ended its clinical development of Hanmi Pharmaceutical Co. Ltd.’s efpeglenatide as a type 2 diabetes treatment, and the Korean firm is now considering how to move forward with developing the once-weekly GLP-1 receptor agonist, which employs Hanmi's Lapscovery delivery technology.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Arbor, Astrazeneca, Avillion, Bayer, Biohaven, Boehringer Ingelheim, Corcept, Corvus, Diffusion, Forte, Gemini, Haliodx, Histogen, Imcheck, Ocular, Recce, Roche, Sanofi, Satsuma, Seneca, Sobi, Sutro, Takeda, Theratechnologies, VBL, Vertex, Zogenix.

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) climbed 72.8% to $31.86 on Sept. 9 following news that its FDA-approved schizophrenia drug, Caplyta (lumateperone), could also help improve bipolar depression.

DUBLIN – Shares in Amryt Pharma plc surged by more than 36% Sept. 9 on news that Filsuvez (AP-101, Oleogel-S10) attained the primary endpoint of a phase III trial in epidermolysis bullosa.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AGTC, Alligator, Ampio, Amryt, Astrazeneca, Aztherapies, Brain Neurotherapy, Cellectar, Clearside, Enterome, Flexion, Intensity, Intra-Cellular, Leukemia & Lymphoma Society, Lipac, Merck, Myokardia, Neurosense, Octapharma, Regenxbio, Roche, Scholar Rock, Sinovac, Trillium, Viking.